Tags

Type your tag names separated by a space and hit enter

Benefits, challenges, and registerability of the polypill.
Eur Heart J. 2006 Jul; 27(14):1651-6.EH

Abstract

Guidelines for the management of cardiovascular disease (CVD) stress the importance of treating global risk, rather than individual risk, factors. Patients at high cardiovascular (CV) risk, for example, benefit from a combination of aspirin, antihypertensive agents, lipid-lowering drugs, and possibly folic acid. As the number of medications that a patient requires increases, adherence and compliance to therapy are likely to decrease. The use of affordable, multiple-target, fixed-combination 'polypills', which concomitantly reduce multiple risk factors without increasing the pill burden or the risk of adverse effects, has the potential to improve CV risk factor management, thereby reducing the incidence of CVD. This review discusses the benefits of the polypill and the challenges and requirements for its success and registerability. Discussions with regulatory bodies are required in order to obtain some 'balance' between an overcautious registration approach and the potentially large public health benefits that are likely to arise from the use of polypills.

Authors+Show Affiliations

Sleight P
Cardiac Department, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK. peter.sleight@attglobal.net
Pouleur H
No affiliation info available
Zannad F
No affiliation info available

MeSH

Adrenergic beta-AntagonistsAgedAngiotensin-Converting Enzyme InhibitorsAspirinAttitude of Health PersonnelCardiovascular DiseasesDrug ApprovalDrug CombinationsDrug CostsFolic AcidHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMiddle AgedPatient SatisfactionPlatelet Aggregation InhibitorsPractice Guidelines as TopicSodium Chloride Symporter InhibitorsTreatment Outcome

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

16603580

Clinical Trial Links

Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention.

Citation

Sleight, Peter, et al. "Benefits, Challenges, and Registerability of the Polypill." European Heart Journal, vol. 27, no. 14, 2006, pp. 1651-6.
Sleight P, Pouleur H, Zannad F. Benefits, challenges, and registerability of the polypill. Eur Heart J. 2006;27(14):1651-6.
Sleight, P., Pouleur, H., & Zannad, F. (2006). Benefits, challenges, and registerability of the polypill. European Heart Journal, 27(14), 1651-6.
Sleight P, Pouleur H, Zannad F. Benefits, Challenges, and Registerability of the Polypill. Eur Heart J. 2006;27(14):1651-6. PubMed PMID: 16603580.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Benefits, challenges, and registerability of the polypill. AU - Sleight,Peter, AU - Pouleur,Hubert, AU - Zannad,Faiez, Y1 - 2006/04/07/ PY - 2006/4/11/pubmed PY - 2007/2/8/medline PY - 2006/4/11/entrez SP - 1651 EP - 6 JF - European heart journal JO - Eur Heart J VL - 27 IS - 14 N2 - Guidelines for the management of cardiovascular disease (CVD) stress the importance of treating global risk, rather than individual risk, factors. Patients at high cardiovascular (CV) risk, for example, benefit from a combination of aspirin, antihypertensive agents, lipid-lowering drugs, and possibly folic acid. As the number of medications that a patient requires increases, adherence and compliance to therapy are likely to decrease. The use of affordable, multiple-target, fixed-combination 'polypills', which concomitantly reduce multiple risk factors without increasing the pill burden or the risk of adverse effects, has the potential to improve CV risk factor management, thereby reducing the incidence of CVD. This review discusses the benefits of the polypill and the challenges and requirements for its success and registerability. Discussions with regulatory bodies are required in order to obtain some 'balance' between an overcautious registration approach and the potentially large public health benefits that are likely to arise from the use of polypills. SN - 0195-668X UR - https://www.unboundmedicine.com/medline/citation/16603580/Benefits_challenges_and_registerability_of_the_polypill_ DB - PRIME DP - Unbound Medicine ER -